Published in final edited form as:

J Alzheimers Dis. 2021 ; 79(2): 895–903. doi:10.3233/JAD-201267.

Presymptomatic Dutch-type hereditary cerebral amyloid angiopathy related blood metabolite alterations

Pratishtha Chatterjee, Ph.D.^{a,b}, Anne M. Fagan, Ph.D.^{c,d}, Chengjie Xiong, Ph.D.^{d,e}, Matthew McKay, Ph.D.^f, Atul Bhatnagar, Ph.D.^f, Yunqi Wu, Ph.D.^f, Abhay K. Singh, Ph.D.^g, Kevin Taddei, B.Sc.^{b,h}, Ian Martins, Ph.D.^b, Samantha L. Gardener, Ph.D.^b, Mark P. Molloy, Ph.D.^{f,i}, Gerhard Multhaup, Ph.D.^j, Colin L. Masters, Ph.D., M.D.^k, Peter R. Schofield, Ph.D.^{l,m}, Tammie L.S. Benzinger, Ph.D., M.D.^{d,n}, John C. Morris, Ph.D., M.D.^{c,d}, Randall J. Bateman, Ph.D., M.D.^{c,d}, Steven M. Greenberg, Ph.D., M.D.^o, Marieke J. H. Wermer, Ph.D., M.D.^p, Mark A. van Buchem, Ph.D., M.D.^p, Hamid R. Sohrabi, Ph.D.^{a,b,h,q,r}, Ralph N. Martins, Ph.D.^{a,b,h,r,s,*}, Dominantly Inherited Alzheimer Network

^aDepartment of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia ^bSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia ^cDepartment of Neurology, Washington University, St. Louis, MO, USA ^dKnight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA ^eDivision of Biostatistics, Washington University, St. Louis, MO, USA ^fAustralian Proteome Analysis Facility, Macquarie University, North Ryde, NSW, Australia ^gMacquarie Business School, Macquarie University, North Ryde, NSW, Australia ^hAustralian Alzheimer's Research Foundation, Nedlands, WA, Australia ⁱBowel Cancer and Biomarker Laboratory, Kolling Institute, The University of Sydney, St Leonards, NSW, Australia ^jDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada ^kThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VA, Australia ^lNeuroscience Research Australia, Sydney, NSW, Australia. ^mSchool of Medical Sciences, University of New South Wales, Sydney, NSW, Australia ⁿDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, USA ^oDepartment of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, Massachusetts, USA ^pDepartment of Radiology, Leiden University Medical Center, Leiden, Netherlands ^qCentre for Healthy Ageing, School of Psychology and Exercise Science, College of Science, Health, Engineering and Education, Murdoch University, Murdoch, WA, Australia ^rSchool of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia ^sThe KaRa Institute of Neurological Diseases, Macquarie Park, NSW, Australia

Abstract

*Corresponding author: Professor Ralph N. Martins, School of Medical and Health Sciences, Edith Cowan University, Ralph & Patricia Sarich Neuroscience Research Institute, 8 Verdun Street, Nedlands, WA 6009, Australia, r.martins@ecu.edu.au. Telephone: (61 8) 6304 5456; Facsimile: (61 8) 6304 5851.

Conflict of Interest

All authors report no competing financial interest in relation to the work described in this manuscript.

Background: Cerebral Amyloid Angiopathy (CAA) is one of the major causes of intracerebral haemorrhage and vascular dementia in older adults. Early diagnosis will provide clinicians with an opportunity to intervene early with suitable strategies, highlighting the importance of presymptomatic CAA biomarkers.

Objective: Investigation of pre-symptomatic CAA related blood metabolite alterations in Dutch-type hereditary CAA mutation carriers (D-CAA MCs).

Methods: Plasma metabolites were measured using mass-spectrometry (AbsoluteIDQ® p400 HR kit) and were compared between pre-symptomatic D-CAA MCs (n=9) and non-carriers (D-CAA NCs, n=8) from the same pedigree. Metabolites that survived correction for multiple comparisons were further compared between D-CAA MCs and additional control groups (cognitively unimpaired adults).

Results: 275 metabolites were measured in the plasma, 22 of which were observed to be significantly lower in the D-CAA MCs compared to D-CAA NCs, following adjustment for potential confounding factors age, sex and *APOE* ε4 ($p < 0.05$). After adjusting for multiple comparisons, only spermidine remained significantly lower in the D-CAA MCs compared to the D-CAA NCs ($p < 0.00018$). Plasma spermidine was also significantly lower in D-CAA MCs compared to the cognitively unimpaired young adult and older adult groups ($p < 0.01$). Spermidine was also observed to correlate with CSF Aβ40 ($r_s = 0.621$, $p = 0.024$), CSF Aβ42 ($r_s = 0.714$, $p = 0.006$) and brain Aβ load ($r_s = -0.527$, $p = 0.030$).

Conclusion: The current study provides pilot data on D-CAA linked metabolite signals, that also associated with Aβ neuropathology and are involved in several biological pathways that have previously been linked to neurodegeneration and dementia.

Keywords

Vascular dementia; Cerebral amyloid angiopathy; Blood biomarkers; Early diagnosis; Metabolomics; Hereditary cerebral haemorrhage with amyloidosis - Dutch type; Intracerebral haemorrhage

Introduction

Sporadic Cerebral Amyloid Angiopathy (CAA) is associated with the accumulation of amyloid-β (Aβ) in the cerebral vasculature and is one of the major causes of intracerebral haemorrhage and vascular dementia observed in older adults [1]. While the Boston criteria facilitates the diagnosis of possible and probable CAA, a definitive CAA diagnosis can only be achieved by *post-mortem* neuropathological examination [2], impeding further research investigating pre-symptomatic CAA biomarkers. Identification of pre-symptomatic CAA biomarkers will enable early diagnosis, thereby enabling clinicians with an opportunity to inform patients on associated bleeding risks with intravenous thrombolysis or anticoagulation therapy.

The Dutch-type hereditary Cerebral Amyloid Angiopathy (D-CAA, also known as hereditary cerebral haemorrhage with amyloidosis Dutch type, HCHWA-D) mutation carriers (MCs), predominantly found in a few families originating from the Katwijk and Scheveningen villages in the Netherlands, present a unique opportunity to study the pre-

symptomatic phase of CAA. In D-CAA MCs, a point mutation on codon 693 (guanine to cytosine transversion, E693Q) of the amyloid precursor protein gene (*APP*), results in the accumulation of abnormal A β E22Q peptide and thereby severe CAA [3]. Given that inheritance of the D-CAA mutation results in 100% penetrance, pre-symptomatic individuals carrying the D-CAA mutation can be diagnosed by genetic analysis [4]. Further, D-CAA MCs manifest symptoms, particularly intracerebral haemorrhage, at a relatively young age (50–60 years), and therefore present as a suitable model to explore pre-symptomatic CAA-related changes, relatively close to symptom onset, with minimal influence of age associated co-morbidities.

Cerebrospinal fluid (CSF) A β levels and brain A β load via positron emission tomography (PET) have previously been evaluated as potential CAA markers using pre-symptomatic and symptomatic D-CAA and sporadic CAA cohorts. Lower CSF A β 40 and A β 42 concentrations and higher A β PET signals have been reported in pre-symptomatic and symptomatic D-CAA MCs and sporadic CAA individuals compared to non-carrier (D-CAA NCs) and control individuals, respectively [5–7]. However, due to the invasive nature of lumbar punctures and the costs involved with amyloid-PET, potential blood biomarkers for pre-symptomatic CAA need to be investigated, as less invasive and cost-effective measures to detect CAA in its pre-symptomatic phase.

Therefore, the aim of the current study was to utilize metabolomics to reveal systemic biochemical changes associated with pre-symptomatic CAA pathogenesis that could serve as potential blood biomarkers for early CAA diagnosis and also provide insight into the biological pathways associated with the pre-symptomatic stage of CAA, relevant to future preventative trials for both, D-CAA and sporadic CAA. Blood metabolite levels were compared between pre-symptomatic D-CAA MCs (n=9) and NCs (n=8). We hypothesised that individuals within the pre-symptomatic stage of CAA (i.e. prior to stroke and cognitive impairment) will have specific metabolite alterations in the blood compared to D-CAA NCs.

Materials and Methods

Participants

Participants for comparison of plasma metabolites in D-CAA MCs versus D-CAA NCs from the same APP E693Q D-CAA pedigree whose ancestors migrated from the Netherlands to Australia, were enrolled in the Dominantly Inherited Alzheimer Network (DIAN) study at Edith Cowan University, Western Australia (n=18). Upon DNA testing, ten participants were found to be positive for the mutation while eight were negative. One D-CAA MC had a history of stroke and was excluded from the current study in order to utilise a purely pre-symptomatic cohort. Therefore, eight D-CAA NCs and nine D-CAA MCs were included, and plasma metabolite concentrations were compared between these D-CAA NCs and D-CAA MCs from the same pedigree. Further, for the validation of plasma metabolites that survived correction for multiple comparisons analyses, two independent control groups of participants were employed for comparison against the D-CAA MCs. These independent control groups comprised cognitively unimpaired young adults without an autosomal dominant Alzheimer's disease mutation who were also enrolled within the DIAN study, Australia (CU-1, n=7) and cognitively unimpaired older adults from the Kerr Anglican

Retirement Village Initiative in Ageing Health (KARVIAH) cohort, Australia (CU-2, n=100) [8] (Supplementary Figure 1). The study was approved by the human research ethics committees at Macquarie University, Edith Cowan University and Washington University. All participants provided informed written consent.

Plasma metabolite measurements

Endogenous metabolite concentrations were measured in fasted plasma samples employing a targeted metabolomics approach. The samples were collected and stored at -80°C prior to analysis as described previously by Bateman and colleagues [9]. The targeted metabolomics approach employed the AbsoluteIDQ® p400 HR kit (BIOCRATES Life Science AG, Innsbruck, Austria). Metabolites with >40% of measurements below the lower limit of detection (LLOD) were excluded from the analysis [10, 11]. Based on this, 275 metabolite species in the plasma were analysed within the current study (See Supplementary Material for further details).

Neuropsychological assessments

Neuropsychological data were obtained from the DIAN and KARVIAH databases, respectively. Mini-Mental State Examination (MMSE), a measure of general cognitive function (for DIAN and KARVIAH cohorts) [12], as well as the Clinical Dementia Rating (CDR) scale, a semi-structured interview assessing dementia severity (DIAN cohort only) [13], were utilised as measures of cognitive status in the current study.

CSF A β concentration measurements

Cerebrospinal fluid (CSF) A β (A β 40, A β 42) concentrations were obtained from the DIAN database for the D-CAA NCs and MCs from the same pedigree. CSF A β 40 and A β 42 concentrations were measured using INNOTEST® β -AMYLOID_(1–40) and INNOTEST® β -AMYLOID_(1–42) (Fujirebio, Ghent, Belgium) as described previously [9].

Neuroimaging

Brain A β load (measured via Positron Emission Tomography (PET) using ligand ^{11}C -Pittsburgh Compound B) represented by standard uptake value ratios (SUVR) were accessed from the DIAN database for the D-CAA NCs and MCs from the same pedigree. The SUVR utilised in the current study was calculated with FreeSurfer using the cortical mean (mean of the prefrontal, temporal, gyrus rectus and precuneus) as the region of interest with the cerebellar gray matter as the reference region, as described previously [14].

Statistical analysis

Descriptive statistics including means and standard deviations, or proportions were calculated for D-CAA MCs versus D-CAA NCs (from the same pedigree)/ CUs, with comparisons employing linear models or Chi-square tests as appropriate, in Table 1 and Supplementary Table 1. Composite scores were generated by taking the mean of the z-scores of the variables of interest. Linear models were employed to compare continuous variables (plasma metabolites concentrations and composite scores) between D-CAA MCs and D-CAA NCs from the same pedigree corrected for covariates age, sex and apolipoprotein E ϵ 4

genotype (*APOE* ϵ 4) status. Response variables were natural log transformed as necessary to better approximate normality and variance homogeneity. Adjustments for multiple comparisons were carried out using Bonferroni correction for metabolites compared between D-CAA MCs and D-CAA NCs, from the same pedigree, after correcting for covariates. Metabolites that survived correction for multiple comparison analyses ($p < .00018$), were further validated by comparing them between D-CAA MCs and independent control groups (CU-1 and CU-2). Spearman's correlation (r_s) was employed to evaluate the strength of the association between plasma metabolites (that survived correction for multiple comparisons) with CSF A β concentrations and brain A β load. All analyses were carried out on the platform R.

Results

Participant characteristics

Characteristics of D-CAA NCs and D-CAA MCs from the same pedigree are presented in Table 1, wherein no significant differences were observed between the D-CAA NCs and presymptomatic MCs, except for CSF A β concentrations ($p < .05$) and brain A β load ($p < .05$) as expected [6, 7].

Participant characteristics of D-CAA MCs compared to additional D-CAA mutation non-carrier groups (CU-1 and CU-2) are presented in Supplementary Table 1. No significant differences in demographic characteristics were observed between the D-CAA MCs and the additional D-CAA mutation non-carrier groups, except for age, wherein the D-CAA MCs were significantly older than CU-1 group participants ($p < .0001$) and significantly younger than CU-2 group participants ($p < .0001$).

Plasma metabolite differences between D-CAA mutation carriers and non-carriers

On investigating metabolite alterations in the D-CAA MCs compared with the D-CAA NCs from the same pedigree, 22 plasma metabolites out of the 275 metabolites measured, belonging to the biogenic amine, amino acid, hexose, acylcarnitine (AC), sphingomyelin (SM) and phosphatidylcholine (PC) classes, were observed to be significantly lower in the D-CAA MCs, following adjustment for potential confounding factors age, sex and *APOE* ϵ 4 genotype status at a significance level of $p < 0.05$ (Table 2, Figure 1). However, after adjusting for multiple comparisons, only spermidine remained significantly different between D-CAA MCs and NCs ($p < .00018$). On comparing spermidine levels between D-CAA MCs and CUs, spermidine levels continued to be lower in the D-CAA MCs (CU-1: $p = .008$; CU-2: $p < .0001$, Table 3, Figure 2).

Association of CSF A β with plasma spermidine

Within the D-CAA MCs and D-CAA NCs from the same pedigree, a significant positive association was observed between CSF A β 40 and spermidine ($r_s = .621$, $p = 0.024$). Further, a positive association was observed between CSF A β 42 and spermidine ($r_s = .714$, $p = 0.006$).

Association of brain A β load with plasma spermidine

Given that brain A β load was significantly higher in the D-CAA MCs compared to the NCs, we expected that spermidine will be inversely associated with brain A β load given that spermidine was significantly lower in D-CAA MCs. Indeed, an inverse association was observed between brain A β load and spermidine ($r_s = -.527$, $p = 0.030$) within the D-CAA MCs and D-CAA NCs from the same pedigree.

Discussion

The current study is the first to report on blood metabolite alterations associated with the pre-symptomatic stage of D-CAA i.e. prior to stroke and cognitive impairment. Currently, in addition to a lack of a treatment, there is also no early diagnostic test for CAA. Within the present study, two-hundred and seventy-five metabolite species in the blood were compared between D-CAA MCs and NCs, wherein 22 metabolites were observed to be significantly lower in the D-CAA MCs following adjustment for potential confounding factors. However, after adjusting for multiple comparisons, only spermidine remained significantly altered. Spermidine was also observed to have a positive association with CSF A β 40 and A β 42 and an inverse association with brain A β load.

The biogenic amine spermidine has been reported to manifest antioxidant and anti-inflammatory properties, promote mitochondrial metabolic function and respiration, and enhance proteostasis and chaperone activity [15]. Oral supplementation and dietary intake of spermidine has been reported to positively influence cognitive performance in older adults at risk of AD and inversely, with all-cause mortality [16, 17]. Furthermore, decreased spermidine levels in the plasma have been observed in AD patients compared to individuals with mild cognitive impairment (MCI) and healthy controls [18]. While these observations are in line with the findings of lower spermidine levels in D-CAA MCs seen within the present study given that 80% of AD patients show CAA comorbidity [19], the exact mechanisms are currently not known. However, it is known that the neuroregulatory action of spermidine results from its interaction with ionotropic receptors, particularly N-methyl-D-aspartate (NMDA) receptors, and the neuroprotective properties of spermidine are posited to result from the inducement of autophagy in glial or neuronal cells and suppression of inflammation [15, 20]. The ability of spermidine to permeate the mammalian blood brain barrier remains elusive, however it has been suggested that spermidine may act through peripheral routes that involve modulating inflammation via cytokines and immune cells that can reach the cerebral tissue [15, 21, 22].

Additionally, other metabolite alterations observed within the current study, although did not survive correction for multiple comparisons, have been reported to be associated with nitric oxide homeostasis, oxidative stress, inflammation, mitochondrial function, glucose and cell membrane lipid metabolism, biological pathways that have previously been implicated in neurodegenerative diseases [10, 11, 23–29].

It is recognised that this study has limitations given its modest sample size and that further studies are required to validate these exploratory findings in independent groups comprising pre-symptomatic D-CAA MCs and age- and sex-matched NCs. Additionally, future studies

also need to investigate whether similar metabolite alterations are present between individuals with pre-symptomatic sporadic CAA and age- and sex-matched controls. Furthermore, future studies also need to investigate whether similar metabolite alterations can differentiate individuals with pre-symptomatic CAA (D-CAA and sporadic) from age- and sex-matched individuals with preclinical AD (familial and sporadic, prior to symptom manifestation) and symptomatic AD (familial and sporadic). The consideration of longitudinal changes in metabolite alterations in the CAA pathology progression or CAA pathogenesis trajectory will also allow evaluation of metabolite alterations as prognostic markers to track disease severity and serve as potential novel therapeutic targets. Furthermore, while a few studies using proteomics and transcriptomics techniques on *post-mortem* brain tissue with CAA have been carried out [30–32], employing similar proteomics and transcriptomics techniques in blood samples from patients with sporadic CAA and D-CAA will complement the CAA-associated metabolite alterations observed within the current study, contributing to efforts in developing a robust panel of pre-symptomatic blood markers for CAA.

It is also important to acknowledge the challenges involved in investigating biomarkers for pre-symptomatic CAA, given the rare incidence of D-CAA and thereby the inaccessibility to large independent D-CAA cohorts for validation, even though D-CAA MCs serve as a suitable model for such research. Further, access to blood samples from individuals within the pre-symptomatic stage of sporadic CAA may prove to be another challenging aspect. Additionally, expanding the current pilot observations to sporadic CAA will also be a future challenge given the presence of mixed pathologies and comorbid conditions in such cases, wherein there are usually traces of AD pathology in CAA brains and traces of CAA in AD brains [33], therefore raising the question of whether biomarker/metabolite alterations observed are associated with CAA pathology and/or AD pathology. To understand whether metabolite changes are associated with CAA pathology or AD pathology, studies employing “disconnected” cases (severe CAA with no or very mild AD, and vice versa) will be particularly informative. Further, age related vascular comorbidities such as hypertension or diabetes may also contribute to mixed pathology in individuals with sporadic CAA and will therefore need to be accounted for.

To conclude, the current study provides pilot data on D-CAA linked metabolite signals, that also associated with A β neuropathology and are involved in several biological pathways that have previously been linked to neurodegeneration and dementia. Further studies are required to validate observations from the current study.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This study was funded by the National Health and Medical Research Council (NHMRC) project grant APP1129627 and National Institute of Health (NIH) grant for the Dominantly Inherited Alzheimer Network study U19AG032438. We thank the participants and their families for their participation and cooperation, and the DIAN research and support staff at Australian Alzheimer’s Research Foundation (AARF), the Mental Health Research Institute (MHRI) and Washington University for their contributions to this study. We thank all staff of the DIAN

Administration, Clinical, Biomarker, Genetics and Imaging cores for their contributions. We also thank Dr Celeste Karch and Dr Xiong Xu for providing us with the supporting data from the master DIAN database. We thank the staff at the Australian Proteome Analysis Facility (APAF) for their support in this study and acknowledge that this study used NCRIS-enabled APAF infrastructure. We also thank Professor Subhojit Roy for his valuable feedback. We thank Dr Manuel Kratzke and Dr Markus Langsdorf for the technical support they provided remotely.

References

1. Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. *Ann Neurol* 70, 871–880. [PubMed: 22190361]
2. Knudsen KA, Rosand J, Karluk D, Greenberg SM (2001) Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. *Neurology* 56, 537–539. [PubMed: 11222803]
3. Maat-Schieman M, Roos R, van Duinen S (2005) Hereditary cerebral hemorrhage with amyloidosis-Dutch type. *Neuropathology* 25, 288–297. [PubMed: 16382777]
4. Bakker E, van Broeckhoven C, Haan J, Voorhoeve E, van Hul W, Levy E, Lieberburg I, Carman MD, van Ommen GJ, Frangione B, et al. (1991) DNA diagnosis for hereditary cerebral hemorrhage with amyloidosis (Dutch type). *Am J Hum Genet* 49, 518–521. [PubMed: 1679289]
5. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM (2009) Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. *Ann Neurol* 66, 245–249. [PubMed: 19743453]
6. van Etten ES, Verbeek MM, van der Grond J, Zielman R, van Rooden S, van Zwet EW, van Opstal AM, Haan J, Greenberg SM, van Buchem MA, Wermer MJ, Terwindt GM (2017) beta-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy. *Neurology* 88, 169–176. [PubMed: 27903811]
7. Schultz AP, Kloet RW, Sohrabi HR, van der Weerd L, van Rooden S, Wermer MJH, Moursel LG, Yaqub M, van Berckel BNM, Chatterjee P, Gardener SL, Taddei K, Fagan AM, Benzinger TL, Morris JC, Sperling R, Johnson K, Bateman RJ, Dominantly Inherited Alzheimer N, Gurol ME, van Buchem MA, Martins R, Chhatwal JP, Greenberg SM (2019) Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. *Ann Neurol* 86, 616–625. [PubMed: 31361916]
8. Goozee K, Chatterjee P, James I, Shen K, Sohrabi HR, Asih PR, Dave P, ManYan C, Taddei K, Ayton SJ, Garg ML, Kwok JB, Bush AI, Chung R, Magnussen JS, Martins RN (2018) Elevated plasma ferritin in elderly individuals with high neocortical amyloid-beta load. *Mol Psychiatry* 23, 18071812.
9. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 367, 795–804. [PubMed: 22784036]
10. Toledo JB, Arnold M, Kastenmuller G, Chang R, Baillie RA, Han X, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, John-Williams LS, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu H, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu K, Henrion MYR, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, Alzheimer's Disease Neuroimaging I, the Alzheimer Disease Metabolomics C (2017) Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimers Dement* 13, 965–984. [PubMed: 28341160]
11. Chatterjee P, Cheong YJ, Bhatnagar A, Goozee K, Wu Y, McKay M, Martins IJ, Lim WLF, Pedrini S, Tegg M, Villemagne VL, Asih PR, Dave P, Shah TM, Dias CB, Fuller SJ, Hillebrandt H, Gupta S, Hone E, Taddei K, Zetterberg H, Blennow K, Sohrabi HR, Martins RN (2020) Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. *J Neurochem*.
12. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 12, 189–198. [PubMed: 1202204]

13. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P (1997) Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. *Neurology* 48, 1508–1510. [PubMed: 9191756]
14. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, Christensen JJ, Friedrichsen K, Hornbeck RC, Farrar AM, Owen CJ, Mayeux R, Brickman AM, Klunk W, Price JC, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Schofield PR, Buckles V, Morris JC, Benzinger TLS, Dominantly Inherited Alzheimer N (2015) Partial volume correction in quantitative amyloid imaging. *Neuroimage* 107, 55–64. [PubMed: 25485714]
15. Madeo F, Eisenberg T, Pietrocola F, Kroemer G (2018) Spermidine in health and disease. *Science* 359.
16. Wirth M, Benson G, Schwarz C, Kobe T, Grittner U, Schmitz D, Sigrist SJ, Bohlken J, Stekovic S, Madeo F, Floel A (2018) The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial. *Cortex* 109, 181–188. [PubMed: 30388439]
17. Kiechl S, Pechlaner R, Willeit P, Nottdurfter M, Paulweber B, Willeit K, Werner P, Ruckenstein C, Iglseder B, Weger S, Mairhofer B, Gartner M, Kedenko L, Chmelikova M, Stekovic S, Stuppner H, Oberhollenzer F, Kroemer G, Mayr M, Eisenberg T, Tilg H, Madeo F, Willeit J (2018) Higher spermidine intake is linked to lower mortality: a prospective population-based study. *Am J Clin Nutr* 108, 371–380. [PubMed: 29955838]
18. Joaquim HPGC AC, Forlenza OV, Gattaz WF, Talib LL (2019) Decreased plasmatic spermidine and increased spermine in mild cognitive impairment and Alzheimer's disease patients. *Archives of Clinical Psychiatry* 46, 120–124.
19. Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. *J Neural Transm (Vienna)* 109, 813–836. [PubMed: 12111471]
20. Eisenberg T, Knauer H, Schauer A, Buttner S, Ruckenstein C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci L, Fussi H, Deszcz L, Hartl R, Schraml E, Criollo A, Megalou E, Weiskopf D, Laun P, Heeren G, Breitenbach M, Grubeck-Loebenstein B, Herker E, Fahrenkrog B, Frohlich KU, Sinner F, Tavernarakis N, Minois N, Kroemer G, Madeo F (2009) Induction of autophagy by spermidine promotes longevity. *Nat Cell Biol* 11, 1305–1314. [PubMed: 19801973]
21. Shin WW, Fong WF, Pang SF, Wong PC (1985) Limited blood-brain barrier transport of polyamines. *J Neurochem* 44, 1056–1059. [PubMed: 3973604]
22. Diler AS, Ziyhan YZ, Uzum G, Lefauconnier JM, Seylaz J, Pinard E (2002) Passage of spermidine across the blood-brain barrier in short recirculation periods following global cerebral ischemia: effects of mild hyperthermia. *Neurosci Res* 43, 335–342. [PubMed: 12135777]
23. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identify antecedent memory impairment in older adults. *Nat Med* 20, 415–418. [PubMed: 24608097]
24. Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, O'Brien R, Pletnikova O, Troncoso JC, Toledo J, Baillie R, Arnold M, Kastenmueller G, Nho K, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R, Legido-Quigley C, Thambisetty M (2018) Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. *PLoS Med* 15, e1002482. [PubMed: 29370177]
25. Chatterjee P, Goozee K, Lim CK, James I, Shen K, Jacobs KR, Sohrabi HR, Shah T, Asih PR, Dave P, ManYan C, Taddei K, Lovejoy DB, Chung R, Guillemin GJ, Martins RN (2018) Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-beta load: A pilot study. *Sci Rep* 8, 8008. [PubMed: 29789640]
26. Chatterjee P, Zetterberg H, Goozee K, Lim CK, Jacobs KR, Ashton NJ, Hye A, Pedrini S, Sohrabi HR, Shah T, Asih PR, Dave P, Shen K, Taddei K, Lovejoy DB, Guillemin GJ, Blennow K, Martins RN (2019) Plasma neurofilament light chain and amyloid-beta are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. *J Neuroinflammation* 16, 186. [PubMed: 31601232]
27. Balez R, Ooi L (2016) Getting to NO Alzheimer's Disease: Neuroprotection versus Neurotoxicity Mediated by Nitric Oxide. *Oxid Med Cell Longev* 2016, 3806157. [PubMed: 26697132]

28. Selley ML (2003) Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. *Neurobiol Aging* 24, 903–907. [PubMed: 12928048]
29. Cristofano A, Sapere N, La Marca G, Angiolillo A, Vitale M, Corbi G, Scapagnini G, Intrieri M, Russo C, Corso G, Di Costanzo A (2016) Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia. *PLoS One* 11, e0155694. [PubMed: 27196316]
30. Hondius DC, Eigenhuis KN, Morrema THJ, van der Schors RC, van Nierop P, Bugiani M, Li KW, Hoozemans JJM, Smit AB, Rozemuller AJM (2018) Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer's disease. *Acta Neuropathol Commun* 6, 46. [PubMed: 29860944]
31. Manousopoulou A, Gatherer M, Smith C, Nicoll JAR, Woelk CH, Johnson M, Kalaria R, Attems J, Garbis SD, Carare RO (2017) Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomeningeal arteries affected by cerebral amyloid angiopathy. *Neuropathol Appl Neurobiol* 43, 492–504. [PubMed: 27543695]
32. Grand Moursel L, van Roon-Mom WMC, Kielbasa SM, Mei H, Buermans HPJ, van der Graaf LM, Hettne KM, de Meijer EJ, van Duinen SG, Laros JFJ, van Buchem MA, t Hoen PAC, van der Maarel SM, van der Weerd L (2018) Brain Transcriptomic Analysis of Hereditary Cerebral Hemorrhage With Amyloidosis-Dutch Type. *Front Aging Neurosci* 10, 102. [PubMed: 29706885]
33. Smith EE (2018) Cerebral amyloid angiopathy as a cause of neurodegeneration. *J Neurochem* 144, 651–658. [PubMed: 28833176]

Figure 1. Plasma metabolites altered between D-CAA mutation non-carriers and carriers from the same pedigree.

Metabolites measured in the plasma were compared between D-CAA mutation non-carriers (D-CAA NCs, n=8) and pre-symptomatic mutation carriers (D-CAA MCs, n=9) employing linear models. Composite scores for acylcarnitine (AC) and sphingomyelin (SM) were generated from the mean of the z-scores of AC and SM species, respectively, as listed in Table 2. Line segments within the plots represents the median and the error bars represent the interquartile range. *represents $p < 0.05$, **represents $p < 0.005$, ***represents $p < 0.001$. SDMA, symmetric dimethyl arginine; AC, acylcarnitine; SM, sphingomyelin; PC-O, phospholipid with choline headgroup and presence of an alkyl ether substituent.

Figure 2. Comparison of plasma spermidine between D-CAA mutation carriers and non-carriers.

Plasma spermidine levels were compared between D-CAA mutation carriers (D-CAA MC) and D-CAA mutation non-carrier groups (D-CAA NC from same pedigree as D-CAA MC, cognitively unimpaired young adults (CU-1) and cognitively unimpaired older adults (CU-2)) using general linear models. The line segment within the plot represents the median and the error bars represent the interquartile range.

Table 1.
Study participant characteristics.

	D-CAA NC	D-CAA MC	p	p ^a
N	8	9	-	-
Sex (M/F)	3/5	3/6	0.858	-
Age (Mean±SD)	43.5±6.57	44.11±4.31	0.822	-
EYO (years; Mean±SD)	-6.09±6.43	-5.27±4.30	0.759	-
<i>APOE</i> ε4 (%)	37.5	22.2	0.490	-
MMSE (Mean±SD)	28.63±1.60	28.67±1.41	0.955	-
CDR global=0 (%)	100	100	-	-
Stroke (%)	0	0	-	-
CSF Aβ40 (pg/mL; Mean±SD)	9882.92±3076.97	6971.35±1088.65	0.051	0.039
CSF Aβ42 (pg/mL; Mean±SD)	618.63±206.81	311.67±154.85	0.012	0.007
CSF Aβ42/Aβ40 (Mean±SD)	0.068±0.027	0.045±0.018	0.108	0.034
Brain Aβ load (SUVR, Mean±SD)	0.985±0.078	1.209±0.221	0.016	0.014

Characteristics including sex, age, expected years to symptom onset (EYO) based on age at symptom onset of biological mutation carrier parent, *APOE* ε4 status, Mini Mental State Examination (MMSE) scores, Clinical Dementia Rating (CDR) scale scores, history of stroke, cerebrospinal fluid (CSF) Aβ40 levels, CSF Aβ42 levels, CSF Aβ42/Aβ40 ratios, CSF total tau (t-tau) levels, CSF phosphorylated tau (p-tau) levels, CSF p-tau/t-tau ratios, plasma Aβ40, plasma Aβ42 levels and plasma Aβ42/Aβ40 ratios have been compared between Dutch-type hereditary cerebral amyloid angiopathy (D-CAA) mutation non-carriers (NCs) and pre-symptomatic carriers (MCs) from the same pedigree. Chi-square tests or linear models were employed as appropriate. CSF parameters presented were only compared between seven NCs and six MCs, due to missing data. CSF Aβ42 and Aβ40 were measured using the INNOTEST β-AMYLOID(1–40) and INNOTEST β-AMYLOID(1–42) (Fujirebio, Ghent, Belgium). Brain Aβ load was measured via Positron Emission Tomography and is presented as the standard uptake value ratio (SUVR) of the ligand, ¹¹C-Pittsburgh Compound B, uptake in the cortical region (mean of the prefrontal, temporal, gyrus rectus and precuneus) as the region of interest with the cerebellar gray matter as the reference region. p^a represents p-values adjusted for age, sex and *APOE* ε4 carrier status. p<0.05 were considered as significant.

Table 2.

Plasma metabolites altered between D-CAA mutation non-carriers and carriers.

	D-CAA NC		D-CAA MC		p	p ^a	p ^b	p ^c
<i>Biogenic amines</i>	Mean	SD	Mean	SD				
Spermidine	0.159	0.038	0.082	0.038	0.001	0.001	0.001	0.0001
SDMA	0.523	0.065	0.419	0.046	0.002	0.002	0.003	0.005
<i>Amino acids</i>								
Phenylalanine	62.475	6.635	54.133	3.291	0.004	0.006	0.007	0.011
Tryptophan	65.463	12.288	54.956	7.003	0.044	0.022	0.022	0.035
<i>Sum of hexoses</i>								
Hexoses	7999.5	983.656	6980.333	583.862	0.019	0.019	0.006	0.008
<i>Acylcarnitines</i>								
AC(4:0)	0.397	0.127	0.286	0.124	0.089	0.076	0.083	0.041
AC(5:0)	3.958	0.966	2.893	0.761	0.023	0.021	0.026	0.040
AC(14:0)	0.026	0.005	0.019	0.006	0.015	0.019	0.023	0.006
AC(16:0)	0.080	0.019	0.063	0.011	0.033	0.035	0.043	0.049
Composite AC score	0.532	0.474	-0.473	0.538	0.001	0.001	0.002	0.001
<i>Sphingolipids</i>								
SM(30:1)	0.845	0.240	0.648	0.206	0.089	0.050	0.024	0.021
SM(32:2)	1.261	0.441	0.887	0.242	0.044	0.047	0.018	0.007
SM(34:2)	17.838	3.920	15.078	3.486	0.145	0.127	0.063	0.042
SM(35:1)	4.895	0.600	4.077	1.205	0.103	0.097	0.065	0.041
SM(36:1)	53.663	10.127	41.456	10.332	0.027	0.033	0.024	0.007
SM(36:2)	8.201	1.603	6.891	1.690	0.123	0.138	0.056	0.016
SM(37:1)	4.389	0.816	3.586	1.067	0.105	0.121	0.076	0.014
SM(38:2)	11.311	2.861	9.199	2.449	0.122	0.121	0.105	0.033
SM(40:2)	34.4	9.455	26.342	9.227	0.096	0.087	0.076	0.040
SM(42:1)	24.925	5.170	20.289	5.060	0.082	0.084	0.094	0.034
SM(42:2)	70.613	13.924	58.844	14.689	0.112	0.116	0.093	0.048
SM(44:2)	1.675	0.279	1.287	0.341	0.022	0.028	0.021	0.017
Composite SM score	0.447	0.697	-0.398	0.781	0.033	0.037	0.018	0.004
<i>Phospholipids</i>								
PC-O(42:4)	0.621	0.275	0.368	0.157	0.032	0.028	0.018	0.024

Metabolites measured in the plasma were compared between D-CAA mutation non-carriers (D-CAA NCs, n=8) and pre-symptomatic mutation carriers (D-CAA MCs, n=9) employing linear models. p^a indicates p-values adjusted for age; p^b indicates p values adjusted for age and sex; p^c indicates p values adjusted for age, sex and *APOE* ε4 status. Only metabolites with p^c<0.05 have been presented in the current table and were considered as statistically significant. All metabolite concentrations are presented in μM. SDMA, symmetric dimethyl arginine; PC-O, phospholipid with choline headgroup and presence of an alkyl ether substituent.

Table 3.
Comparison of plasma spermidine levels between D-CAA and CU adults.

D-CAA MC	CU-1	CU-2	p	p ^{adj}	p ^a	p ^b
N=9	N=7	N=100				
0.082±0.038	0.177±0.029	0.195±0.054	<.0001	<.0001	.008	<.0001

Plasma spermidine levels (presented in mean±SD, μM) in D-CAA MCs were compared with plasma spermidine levels in cognitively unimpaired younger adults (CU-1) and cognitively unimpaired older adults (CU-2). p and p^{adj} represent univariate p-values before and after adjusting for age, sex and *APOE* ε4 carrier status. p^a and p^b represent pairwise comparisons between D-CAA MC and CU-1, D-CAA MC and CU-2, respectively.